StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

Research analysts at StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Down 3.1 %

NASDAQ CHEK opened at $0.76 on Monday. Check-Cap has a 12-month low of $0.56 and a 12-month high of $3.45. The company’s 50 day moving average is $1.02 and its 200-day moving average is $1.16. The firm has a market cap of $4.42 million, a P/E ratio of -0.25 and a beta of 0.19.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.